VistaGen Therapeutics is a late clinical-stage biopharmaceutical company developing non-systemic intranasal pherine product candidates that activate nose-to-brain neurocircuits without systemic absorption. Its pipeline includes five clinical-stage candidates: fasedienol (Phase 3, social anxiety disorder), itruvone (Phase 2A, major depressive disorder), PH80 (Phase 2A, vasomotor symptoms and premenstrual dysphoric disorder), PH15 (Phase 2A, mental fatigue), and PH284 (Phase 2A, cancer cachexia). Fasedienol is the lead candidate in the registration-directed PALISADE Program.
Q2 FY2026 — expected 2026-09-10
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-06-17 | 2025-03-31 | 0001411685-25-000041 | EDGAR | 86K words |
| 2024-06-11 | 2024-03-31 | 0001411685-24-000022 | EDGAR | — |
| 2023-06-28 | 2023-03-31 | 0001437749-23-018793 | EDGAR | — |
| 2022-06-23 | 2022-03-31 | 0001851734-22-000349 | EDGAR | — |
| 2021-06-29 | 2021-03-31 | 0001654954-21-007380 | EDGAR | — |
| 2020-06-29 | 2020-03-31 | 0001654954-20-007107 | EDGAR | — |
| 2019-06-25 | 2019-03-31 | 0001654954-19-007632 | EDGAR | — |
| 2018-06-26 | 2018-03-31 | 0001654954-18-006990 | EDGAR | — |
| 2017-06-29 | 2017-03-31 | 0001654954-17-005976 | EDGAR | — |
| 2016-06-24 | 2016-03-31 | 0001415889-16-006331 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-02-12 | 2025-12-31 | 0001628280-26-007718 | EDGAR | 60K words |
| 2025-11-13 | 2025-09-30 | 0001628280-25-052079 | EDGAR | — |
| 2025-08-07 | 2025-06-30 | 0001411685-25-000064 | EDGAR | — |
| 2025-02-13 | 2024-12-31 | 0001411685-25-000019 | EDGAR | — |
| 2024-11-07 | 2024-09-30 | 0001411685-24-000048 | EDGAR | — |
| 2024-08-13 | 2024-06-30 | 0001411685-24-000037 | EDGAR | — |
| 2024-02-13 | 2023-12-31 | 0001437749-24-003916 | EDGAR | — |
| 2023-11-09 | 2023-09-30 | 0001437749-23-031293 | EDGAR | — |
| 2023-08-10 | 2023-06-30 | 0001437749-23-023127 | EDGAR | — |
| 2023-02-07 | 2022-12-31 | 0001851734-23-000035 | EDGAR | — |
| 2022-11-10 | 2022-09-30 | 0001851734-22-000662 | EDGAR | — |
| 2022-08-11 | 2022-06-30 | 0001851734-22-000432 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-04-02 | 0001628280-26-023176 | EDGAR | 1K words |
| 2026-03-18 | 0001628280-26-019455 | EDGAR | — |
| 2026-03-16 | 0001628280-26-018163 | EDGAR | — |
| 2026-03-11 | 0001628280-26-016652 | EDGAR | — |
| 2026-02-20 | 0001628280-26-010035 | EDGAR | — |
| 2026-02-12 | 0001628280-26-007715 | EDGAR | — |
| 2026-02-06 | 0001628280-26-006078 | EDGAR | — |
| 2026-01-09 | 0001628280-26-001690 | EDGAR | — |
| 2025-12-22 | 0001628280-25-058594 | EDGAR | — |
| 2025-12-03 | 0001628280-25-055083 | EDGAR | — |
386 total filings indexed. 354 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001411685 |
| Ticker | VTGN |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | NV |
| Website | https://www.vistagen.com |
| Listed | 2009-07-01 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report